Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex & ORCID
How has David C. Wheeler's publication output changed over time?
ScholarIQpublication output · 2003–2022
Output grew0% over the shown period — from 1 works in 2003 to 1 in 2022.
1
1
1
1
2
3
2
1
20032007201120152017201920202022
What are the most-cited papers on David C. Wheeler?
ScholarIQmost cited works
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
Vlado Perkovic, Meg Jardine, Bruce Neal, Séverine Bompoint, Hiddo J.L. Heerspink, David M. Charytan, Robert Edwards, Rajiv Agarwal, George L. Bakris, Scott Bull, Christopher P. Cannon, George Capuano, Pei-Ling Chu, Dick de Zeeuw, Tom Greene, Adeera Levin, Carol A. Pollock, David C. Wheeler, Yshai Yavin, Hong Zhang, Bernard Zinman, Gary Meininger, Barry M. Brenner, Kenneth W. Mahaffey
New England Journal of Medicine. 20196,091 CitationsOPEN ACCESS
Dapagliflozin in Patients with Chronic Kidney Disease
Hiddo J.L. Heerspink, Bergur V. Stefánsson, Ricardo Correa‐Rotter, Glenn M. Chertow, Tom Greene, Fan Fan Hou, Johannes F.E. Mann, John J.V. McMurray, Magnus Lindberg, Peter Rossing, C. David Sjöström, Roberto D. Toto, Anna-Maria Langkilde, David C. Wheeler
New England Journal of Medicine. 20205,353 CitationsOPEN ACCESS
The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial
Colin Baigent, Martin Landray, Christina Reith, Jonathan Emberson, David C. Wheeler, Charles Tomson, Christoph Wanner, Vera Krane, Alan Cass, Jonathan C. Craig, Bruce Neal, Lixin Jiang, Lai Seong Hooi, Adeera Levin, Lawrence Y. Agodoa, Mike Gaziano, Bertram L. Kasiske, Robert Walker, Ziad A. Massy, Bo Feldt‐Rasmussen, Udom Krairittichai, Vuddidhej Ophascharoensuk, Bengt Fellström, Hallvard Holdaas, Vladimı́r Tesař, Andrzej Więcek, Diederick E. Grobbee, Dick de Zeeuw, Carola Grönhagen‐Riska, Tanaji Dasgupta, David Lewis, William G. Herrington, Marion Mafham, William Majoni, Karl Wallendszus, Richard H. Grimm, Terje Pedersen, Jonathan A. Tobert, Jane Armitage, Alex Baxter, Christopher Bray, Yiping Chen, Zhengming Chen, Michael Hill, Carol Knott, Sarah Parish, David Simpson, Peter Sleight, Alan Young, Rory Collins
The Lancet. 20112,477 Citations
Chronic kidney disease as a global public health problem: Approaches and initiatives – a position statement from Kidney Disease Improving Global Outcomes
Andrew S. Levey, R. C. Atkins, Josef Coresh, Eric P. Cohen, A.J. Collins, Kai‐Uwe Eckardt, Meguid El Nahas, Bertrand L. Jaber, Michel Jadoul, Adeera Levin, Neil R. Powe, Jérôme Rossert, David C. Wheeler, Norbert Lameire, Garabed Eknoyan
Kidney International. 20071,534 CitationsOPEN ACCESS
Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials
Colin Baigent, Jonathan Emberson, Richard Haynes, William G. Herrington, Parminder K. Judge, Martin Landray, Kaitlin J. Mayne, Sarah Y A Ng, David Preiss, Alistair Roddick, Natalie Staplin, Doreen Zhu, Stefan D. Anker, Deepak L. Bhatt, Martina Brueckmann, Javed Butler, David Z.I. Cherney, Jennifer B. Green, Sibylle J. Hauske, Richard Haynes, Hiddo J.L. Heerspink, William G. Herrington, Silvio E. Inzucchi, Meg Jardine, Chih‐Chin Liu, Kenneth W. Mahaffey, Finnian R. McCausland, Darren K. McGuire, John J.V. McMurray, Bruce Neal, Brendon L. Neuen, Milton Packer, Vlado Perkovic, Marc S. Sabatine, Scott D. Solomon, Muthiah Vaduganathan, Christoph Wanner, David C. Wheeler, Stephen D. Wiviott, Faı̈ez Zannad
The Lancet. 20221,000 CitationsOPEN ACCESS
Related on ScholarIQ
Felix Platter-Hospital
Institution
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
Paper
Dapagliflozin in Patients with Chronic Kidney Disease
Paper
The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial
Paper
Chronic kidney disease as a global public health problem: Approaches and initiatives – a position statement from Kidney Disease Improving Global Outcomes
Paper
Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials
Paper